Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) EBITDA (2024 - 2026)

Beta Bionics' EBITDA history spans 3 years, with the latest figure at -$22.4 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 21.37% to -$22.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$66.8 million, a 5.59% increase, with the full-year FY2025 number at -$72.9 million, down 32.89% from a year prior.
  • EBITDA hit -$22.4 million in Q1 2026 for Beta Bionics, down from -$13.4 million in the prior quarter.
  • Over the last five years, EBITDA for BBNX hit a ceiling of -$9.7 million in Q3 2024 and a floor of -$28.5 million in Q1 2025.
  • Historically, EBITDA has averaged -$16.7 million across 3 years, with a median of -$14.5 million in 2024.
  • The widest YoY moves for EBITDA: up 25.88% in 2025, down 126.38% in 2025.
  • Tracing BBNX's EBITDA over 3 years: stood at -$18.1 million in 2024, then grew by 25.88% to -$13.4 million in 2025, then tumbled by 66.91% to -$22.4 million in 2026.
  • Business Quant data shows EBITDA for BBNX at -$22.4 million in Q1 2026, -$13.4 million in Q4 2025, and -$14.0 million in Q3 2025.